Nektar Therapeutics Q2 revenue falls, net loss narrows

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
• The average consensus recommendation for the biotechnology & medical research peer group is "buy"
• Wall Street's median 12-month price target for Nektar Therapeutics is $151.00, about 98.6% above its August 12 closing price of $76.03

• Company expects initial Phase 3 data readouts for rezpegaldesleukin in mid-2028
• Nektar plans to start a Phase 3 study in alopecia areata in early 2027
• Company anticipates first BLA submission for rezpegaldesleukin in 2029

• US biotech developer's Q2 revenue declined yr/yr, reflecting lower non-cash royalty revenue
• Net loss for Q2 narrowed slightly as higher R&D expenses were offset by lower G&A costs
• Company completed $373.8 mln public offering and started Phase 3 trials for lead candidate

Key details